Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FXR shRNA
- Development stage
- Preclinical
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Parenteral
01
Overview
FXR shRNA is a research-grade RNA interference tool designed to silence the expression of the farnesoid X receptor (FXR), a nuclear receptor that regulates bile acid homeostasis. In the context of esophageal cancer research, FXR shRNA has been utilized to demonstrate that FXR mediates the carcinogenic effects of bile acids, such as the induction of COX-2 and suppression of tumor suppressors like RAR-β2 and RRIG1. By knocking down FXR, researchers have shown a reduction in cancer cell viability and an antagonism of bile acid-induced gene expression changes, suggesting FXR as a potential target for chemoprevention in esophageal adenocarcinoma and squamous cell carcinoma.
- Other names
- farnesoid X receptor short hairpin RNA
02
Targets
FXR (Farnesoid X receptor)
Beyond the preview
Go deeper on FXR shRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FXR shRNA.